Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.40

-1.5%

Dec 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (3732)	5/10/2001 8:22:20 PM
From: Miljenko Zuanic	Read Replies (1) of 52153

<<Only wish it had been a biotech rather than a big bad pharma that had delivered this revolutionary drug...>> Gleevec isn't as revolutionary new cancer drug as it is sub-specific for cancer type where one gene went wrong. Definitely it is a very potent drug for CML, but media and street will overdue as they usually do. The point is that specific and selective targeting is way to treat cancer, however and unfortunately very few cancer type have this characteristic. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next